[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501208":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":10,"locations":19,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Dab\u002Ftram",null,"Patients received dabrafenib and trametinib treatment",{"label":13,"type":10,"description":14,"interventionNames":10},"Enco\u002Fbini","Patients received encorafenib and binimetenib treatment",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20],{"facility":17,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"East Hanover","New Jersey","07936","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-74.36487,40.8201,{"lat":30,"lon":29},{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100501208","patient-characteristics-associated-factors-and-clinical-outcomes-of-prescribing-encorafenib-and-binimetenib-versus-dabrafenib-and-trametinib-among-braf-v600-mutated-metastatic-melanoma-patients-100501208",false,"NCT05806268","Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients","Inclusion criteria\n\n* Diagnosis of melanoma (ICD-9 172.x \\& ICD-10 C43 or D03x)\n* Pathologic stage III (unresectable) or IV at initial diagnosis on or after 01 January 2011\n* 1L treatment with enco\u002Fbini or dab\u002Ftram on or after 01 June 2018\n* Evidence of a BRAF test\n* Evidence of a BRAF-positive result prior to or up to 30 days after 1L therapy initiation\n* At least 18 years of age at the time of initiation of 1L treatment Exclusion criteria\n* Documented receipt of a clinical trial treatment for cancer at any time on or after September 2015\n* Diagnosis of a second primary cancer or secondary cancer following initiation of 1L metastatic melanoma (MM) treatment","ALL","18 Years",{"count":43,"type":44},214,"ACTUAL","OBSERVATIONAL","This was a retrospective real-world evidence cohort study. The study was conducted using the NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset, with a study period from 01 January 2011 to 31 May 2020. All included patients were ≥18 years of age and were required to have a diagnosis of unresectable stage III or IV melanoma (ICD-9 172.x \\& ICD-10 C43 or D03x), treatment with dabrafenib and trametinib (dab\u002Ftram) or encorafenib and binimetenib (enco\u002Fbini) on or after 01 June 2018, and evidence of a BRAF-positive result prior to or up to 30 days after therapy initiation.\n\nNo quota of centers was established a priori. Given the retrospective nature of this study, all patients who met the inclusion\u002Fexclusion criteria from the NOBLE dataset were included.",[48],"BRAF v600 Mutated Metastatic Melanoma","COMPLETED","2023-03-28",{"date":52,"type":44},"2023-04-10",{"date":54,"type":44},"2021-07-30",{"date":56,"type":44},"2022-03-28",{"name":17,"class":6},1]